Is RGNX or RNA more undervalued in 2026?

CirclFi compares REGENXBIO Inc. (RGNX) and Atrium Therapeutics, Inc. (RNA) using 13 institutional-grade valuation models. RGNX has a Quality of Company score of 6.4/10 while RNA scores 1.7/10.

Which is a better buy — RGNX or RNA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RGNX and RNA valuations compare?

RGNX at $6.89 and RNA at $13.36 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RGNX vs RNA Valuation Comparison 2026 — Intrinsic Value Analysis

RGNX

Biotechnology

REGENXBIO Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$6.89

Last close

Models

9/13

Active

RNA

Biotechnology

Atrium Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$13.36

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	RGNX Fair Value	RGNX Upside	RNA Fair Value	RNA Upside
Bayesian DCF	Intrinsic	$0.88	-87.3%	$3.54	-73.5%
Earnings Power Value	Intrinsic	—	—	$5.25	-61.1%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.93	-72.0%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RGNX vs RNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RGNX vs RNA — Which Stock Is More Undervalued?

RGNX scores higher with a 6.4/10 quality rating vs RNA's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing REGENXBIO Inc. (RGNX) and Atrium Therapeutics, Inc. (RNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RGNX currently trades at $6.89 with a QOC of 6.4/10, while RNA trades at $13.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).